Luteinising hormone releasing hormone (LHRH) analogues are routinely used in the treatment of patients with advanced prostate cancer. This randomised crossover trial was conducted to compare patient ...
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases ...
Socioeconomic status and concomitant diseases in patients with prostate cancer. 0-6 94,4; n=504 0,40 [0,10-1,31]; n= 512 0,21 [0,10-0,49]; n=81 55-60 90,6; n=476 0,17 [0,05-0,91]; n= 516 0,20 ...
The use of LHRH analogues as antagonists is well studied. Use of intermittent LHRH analogue (Lupron) as an agonist in the diagnosis or treatment of gonadal disorders is being investigated. To validate ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke, a clinical trial has found. The drug ...
Tolmar Pharmaceuticals Inc., a specialty pharmaceutical company, today announced publication in the April issue of the Journal of Urology of a real-world analysis of medical records of patients with ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results